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OBJECTIVE 
1. To analyze the clinical relevance, in clinical practice, of 
serum levels of adalimumab (ADA) and the production 
of anti-ADA antibodies (anti-ADA-Abs).  
2. To evaluate if there is a correlation between serum levels 
of ADA and result of DAS28.  
3. To determine the minimum appropriate serum levels of 
ADA to keep the patients in clinical remission or in low 
clinical activity. 
PATIENTS AND METHODS   
• Prospective study in RA patients, treated more than 6 
months with ADA 
• Clinical characteristics of the patients and RA 
• Activity index of RA: DAS28-ESR 
      -   Responders: DAS28-ESR < 2.6 (remision) 
      -   Low activity: DAS28 2.7-3.2: DAS28-ESR  
• Serum levels of ADA and anti-ADA-Abs (ELISA kit. 
Promonitor®-ADA. Proteomika, Derio. Vizcaya. Spain)  
      -   Cut-off level for serum Abs for anti-ADA: >32 U/mL  
      -   Cut-off level for serum level of ADA <0.004 mg/L.  
• All the patients were receiving some DMARD 
(methotrexate, leflunomide or hydroxychloroquine). 
• Serum samples were collected before injection of ADA 
(the same day), and stored frozen until analysis. 
• The patients was distributed in three tertiles groups from 
serum levels of ADA: <2,8 mg/L; 2,9-7,3 mg/L; >7,3 
mg/L.  
• ROC curve was used to select the optimus cut-off level of 
ADA to keep the patients on remission or low activity 
level of disease.  
• The correlation between DAS28 and serum level of ADA 
was evaluated. 
CONCLUSIONS  
1.  The cut-off of ROC curve for serum level of ADA, to keep the patients in low activity of disease is 3,45 mg/L.     2.  There is a negative correlation between the serum level of ADA and DAS28. 
3.  Serum level of ADA >7,3 mg/L does not increase the improvement of DAS28. In these patients, we can consider to decrease the ADA dose or its delay.  






























DAS28  <  3.2 3.489  83.18% 83.33% 77.8% 
DAS28  <  2.6 3.015      65.77% 50% 77.27% 
 
RA (N: 56) 
 
Group 1 (N: 22) 
ADA < 2,8 mg/L 
 
Group 2 (N: 13) 
ADA 2,8-7,3 mg/L 
 
Group 3 (N: 21) 
ADA > 7,3 mg/L 
ADA level (mg/L) 1,56±1,18 4,64±1,15(1) 12,24±4,45(3,5) 
Ab anti-ADA (%) 4 (18%) 0 0 
DAS28-ESR 3,81±1,33 2,64±0,92(2) 2,53±0,68(4,6) 
RESULTS 
•  DMARDs (%):     98   
     -  Metotrexate  (%/mg, mean):  65/15 
     -   Leflunomide (%/mg mean):  21/18  
     -   OHChloroquine (%/mg mean):  14/200  
• Ab anti-ADA (nº pacients/%): 4/7% 
• ADA level with Ab anti-ADA:  <2.8 
30% 
• Nº pacients:     56 
• Nº determinations:   63 
•    Woman (%):     75 
•    Mean age (years):    62 
• Time evolution RA (months):        156±122  
• Time on  ADA (months):       32,2±18,3  
• ADA, first anti-TNF (%):  80 
(A): Group 2 vs group 1: (1)p<0,01. (2)p=0,006.         
(B): Group 3 vs group 1: (3)p<0,01. (4)p<0,001. 
(C): Group 3 vs group 2: (5)p<0,01. (6)p: 0,5. 
 
ADA: Adalimumab 
Table 1. Relation of ADA level, Ab anti-ADA and DAS28-ESR, according to tertiles of ADA. 
Figure 1 and Table 2. ROC curves: cut-off, area under cirve, sensibility and specificity for the ADA level on 


















Figure 2. Coeficiente of correlation  between DAS28  and ADA level   
Figure 3. DAS28 evolution according to the Tertiles of ADA level. Contrast of means 
r: - 0.46 (IC 95%: - 0.66 , - 0.21).  
ADA <2.8 vs 2.8-7.3  P<0.001 
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